

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: Gregory D. Plowman, et al.  
Title: MAMMALIAN PROTEIN  
PHOSPHATASES  
Appl. No.: Unassigned, divisional of 09/986,992  
Filing Date: November 20, 2003  
Examiner: Unassigned  
Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the USPTO in parent application Serial No. 09/986,992, filed November 13, 2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the USPTO in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

**RELEVANCE OF EACH DOCUMENT**


The relevance of the foreign-language document is explained in the parent application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 11/20/03

By 

FOLEY & LARDNER  
Customer Number: 22428  
Telephone: (202) 672-5475  
Facsimile: (202) 672-5399

Beth A. Burrous  
Attorney for Applicant  
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: November 20, 2003  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	Unassigned, divisional of 09/986,992
				<b>Filing Date</b>	November 20, 2003
				<b>First Named Inventor</b>	Gregory D. Plowman
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
				<b>Attorney Docket Number</b>	034536-0179
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	4,447,608	A	JONES et al.	05/08/1984	
	A2	5,700,821	A	LAZO et al.	12/23/1997	
	A3	2002/0077463	A1	MEYERS	06/20/2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A4	WO	01/77290	A2	GENETICS INSTITUTE, INC.	10/18/2001		
	A5	WO	01/54472	A2	HUMAN GENOME SCIENCES, INC.	08/02/2001		
	A6	WO	00/55174	A1	HUMAN GENOME SCIENCES, INC.	09/21/2000		
	A7	WO	91/15495	A1	PFIZER INC.	10/17/1991		
	A8	WO	01/16097	A1	SUGEN, INC.	03/08/2001		
	A9	WO	01/55425	A1	BIODOOR GENE TECHNOLOGY LTD. SHANGHAI	08/02/2001		
	A10	WO	01/96571	A2	BAYER AKTIENGESELLSCHAFT	12/20/2001		
	A11	WO	01/96546	A2	INCYTE GENOMICS, INC.	12/20/2001		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A12	DATABASE WPI , Section Ch, Week 200152, Derwent Publications Ltd., London GB; Class B04, AN 2001-483265, XP002214997		
	A13	DATABASE EMBL [Online], 31 October 2001, ISOGAI T. et al.: Database Accession no. AK054678, XP 002214897		
	A14	BEVAN et al., Database: PIR, Accession number T50783 (July 2000).		
	A15	NCI-CGAP, Database: EST, Accession number AA210814 (August 13, 1997).		

<b>Examiner Signature</b>	<b>Date Considered</b>	
---------------------------	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP, 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.